A 42-year-old man with bipolar II disorder has been on lithium 600 mg daily for 18 months with good mood stabilization. Routine blood work shows: serum creatinine 1.8 mg/dL (baseline 0.9 mg/dL), eGFR 38 mL/min/1.73 m², serum lithium level 0.9 mEq/L (therapeutic), TSH 6.2 mIU/L (normal <4.0), and free T4 0.8 ng/dL (normal 0.8–1.8). Urinalysis shows specific gravity 1.005 (hyposthenuria). Which of the following best explains these findings and represents the most appropriate next step?

Explanation

## Chronic Lithium Toxicity: Renal and Thyroid Complications ### Clinical Findings Interpretation | Finding | Interpretation | |---------|----------------| | ↑ Creatinine (0.9 → 1.8 mg/dL), ↓ eGFR (38 mL/min/1.73 m²) | Chronic kidney disease (Stage 3b) | | ↑ TSH, ↓ free T4 | Primary hypothyroidism | | ↓ Urine specific gravity (1.005) | Nephrogenic diabetes insipidus (NDI) | | Therapeutic lithium level (0.9 mEq/L) | NOT acute toxicity; chronic exposure effect | ### Pathophysiology of Chronic Lithium Nephrotoxicity **Key Point:** Lithium causes dose-dependent, often irreversible chronic kidney disease through two mechanisms: 1. **Nephrogenic Diabetes Insipidus (NDI)** - Lithium inhibits aquaporin-2 water channels in collecting duct - Results in polyuria and inability to concentrate urine (specific gravity <1.010) - Occurs in 20–40% of long-term lithium users - May be partially reversible if lithium stopped early 2. **Chronic Interstitial Fibrosis** - Lithium accumulates in distal tubule and collecting duct - Causes chronic inflammation, tubular atrophy, and fibrosis - Progressive, often irreversible even after lithium discontinuation - Leads to slowly declining GFR **High-Yield:** Chronic lithium nephrotoxicity is NOT an acute event; it develops insidiously over months to years and may progress even after drug cessation. ### Lithium-Induced Hypothyroidism **Mechanism:** - Lithium inhibits thyroid peroxidase (TPO) and iodine uptake - Impairs thyroid hormone synthesis and release - Occurs in 5–30% of patients on long-term lithium - Usually develops within 6–12 months but can occur anytime ### Management Strategy ```mermaid flowchart TD A[Chronic lithium use with NDI + hypothyroidism]:::outcome --> B{Continue or stop lithium?}:::decision B -->|Mood disorder well-controlled, no acute toxicity| C[CONTINUE lithium with modifications]:::action C --> D[Reduce dose if possible to minimize further renal decline]:::action D --> E[Start levothyroxine for hypothyroidism]:::action E --> F[Monitor renal function every 3-6 months]:::action F --> G[Recheck TSH every 6-8 weeks until stable]:::action G --> H[Educate on hydration & NSAID avoidance]:::action B -->|Mood disorder uncontrolled or eGFR <30| I[Consider alternative mood stabilizer]:::action I --> J[Valproate, lamotrigine, or aripiprazole]:::action ``` **Clinical Pearl:** The decision to continue or discontinue lithium depends on: - **Severity of renal impairment** (eGFR 38 is Stage 3b—not yet Stage 4–5) - **Efficacy and tolerability** of lithium for mood stabilization - **Availability of alternatives** and their side effect profiles - **Patient preference and risk tolerance** In this case, eGFR 38 with therapeutic lithium level and good mood control suggests **continuation with dose optimization** rather than abrupt discontinuation. ### Why NOT Discontinue Immediately? 1. **Irreversibility:** Chronic interstitial fibrosis may progress even after lithium stops; stopping does not guarantee renal recovery. 2. **Mood destabilization risk:** Abrupt lithium cessation increases relapse risk (up to 50% within 6 months in bipolar I). 3. **eGFR not critically low:** Stage 3b CKD is manageable with monitoring; Stage 4–5 would mandate stronger action. 4. **Hypothyroidism is treatable:** Levothyroxine replacement is straightforward and safe. ### Monitoring & Preventive Measures **High-Yield:** Minimize further renal deterioration: - **Maintain adequate hydration** — reduces lithium reabsorption in proximal tubule - **Avoid NSAIDs** — reduce GFR and increase lithium reabsorption (risk of toxicity) - **Monitor renal function every 3–6 months** — detect decline early - **Monitor TSH every 6–8 weeks** after levothyroxine initiation, then annually - **Consider dose reduction** if eGFR continues to decline **Mnemonic: LITHIUM Chronic Effects — "HINT"** - **H**ypo**thyroid**ism (↑ TSH) - **I**nsufficiency of renal function (↑ Cr, ↓ eGFR) - **N**ephrogenic diabetes **I**nsipidus (polyuria, low specific gravity) - **T**oxicity risk if dehydrated or on NSAIDs [cite:KD Tripathi 8e Ch 12; Harrison 21e Ch 397]